Inogen, Inc. (NASDAQ:INGN - Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $10.23 and traded as high as $11.07. Inogen shares last traded at $10.64, with a volume of 340,965 shares changing hands.
Analyst Ratings Changes
Several brokerages have issued reports on INGN. StockNews.com raised Inogen from a "hold" rating to a "buy" rating in a research report on Monday, February 10th. Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a research report on Thursday, January 30th.
Read Our Latest Stock Report on INGN
Inogen Trading Down 1.2 %
The stock has a market cap of $250.35 million, a price-to-earnings ratio of -4.68 and a beta of 1.02. The stock has a 50-day moving average price of $10.09 and a two-hundred day moving average price of $10.26.
Institutional Trading of Inogen
Institutional investors have recently made changes to their positions in the business. AlphaQuest LLC acquired a new stake in shares of Inogen in the 4th quarter worth $43,000. Meeder Asset Management Inc. acquired a new stake in shares of Inogen in the 4th quarter worth $56,000. Quarry LP acquired a new stake in shares of Inogen in the 3rd quarter worth $59,000. Integrated Quantitative Investments LLC acquired a new stake in Inogen during the 4th quarter worth about $92,000. Finally, Ieq Capital LLC acquired a new stake in Inogen during the 4th quarter worth about $94,000. Institutional investors and hedge funds own 89.94% of the company's stock.
About Inogen
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Stories
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
